The Trump administration’s push to revive the controversial “most favored nation” (MFN) pricing policy -- alongside ongoing uncertainty around tariffs and Medicare drug price negotiations -- is creating deep uncertainty for the future of generic and biosimilar drug development in the United States, Association for Accessible Medicines (AAM) President and CEO John Murphy told Inside Health Policy in a Monday (June 2) interview.